85021908 - AMT.

Information

• Trademark
• 85021908

• Source

• Serial Number

  85021908

• Registration Number

  4110829

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  April 23, 2010
  14 years ago

• Registration Date

  March 13, 2012
  12 years ago

• Transaction Date

  November 27, 2018
  6 years ago

• Status Date

  October 19, 2018
  6 years ago

• Published for Opposition Date

  December 27, 2011
  12 years ago

• Location Date

  March 13, 2012
  12 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  ERVIN, INGA MARIE

• Attorney Docket Number

  22572/18

  Attorney Name

  Mark S. Leonardo

  Law Office Assigned Location Code

  M20

• Owners

  • AMSTERDAM MOLECULAR THERAPEUTICS (AMT) IP B.V

Case File Statements

• CC0000: Color is not claimed as a feature of the mark.
• DM0000: The mark consists of "amt." surrounded by a solid circle.
• GS0011: Nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cell transformed by viral vectors, gene therapy vectors and nucleic acid delivery vectors for other than medical and veterinary purposes; chemical reagents for scientific or research use, namely, nucleic acids and vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes
• GS0051: Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and call therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders, single gene disorders and cancers; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
• GS0421: Laboratory research in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry; product development and consultancy in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry
• GS0441: Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation
• PM0001: AMSTERDAM MOLECULAR THERAPEUTICS

Case File Event Statements

• 10/19/2018 - 6 years ago

  31 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 3/13/2017 - 7 years ago

  30 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1

• 3/13/2012 - 12 years ago

  29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 12/27/2011 - 12 years ago

  28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/27/2011 - 12 years ago

  27 - PUBLISHED FOR OPPOSITION Type: PUBO

• 12/7/2011 - 13 years ago

  26 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 11/22/2011 - 13 years ago

  25 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 11/21/2011 - 13 years ago

  24 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 11/4/2011 - 13 years ago

  23 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/4/2011 - 13 years ago

  22 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/4/2011 - 13 years ago

  21 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 5/5/2011 - 13 years ago

  20 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 5/5/2011 - 13 years ago

  19 - NON-FINAL ACTION E-MAILED Type: GNRT

• 5/5/2011 - 13 years ago

  18 - NON-FINAL ACTION WRITTEN Type: CNRT

• 4/13/2011 - 13 years ago

  17 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 4/13/2011 - 13 years ago

  16 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 4/13/2011 - 13 years ago

  15 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 2/9/2011 - 13 years ago

  14 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 2/9/2011 - 13 years ago

  13 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/9/2011 - 13 years ago

  12 - NON-FINAL ACTION WRITTEN Type: CNRT

• 1/18/2011 - 13 years ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/18/2011 - 13 years ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 1/11/2011 - 13 years ago

  9 - ASSIGNED TO LIE Type: ALIE

• 12/20/2010 - 14 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 6/22/2010 - 14 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 6/22/2010 - 14 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 6/22/2010 - 14 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 6/22/2010 - 14 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 4/30/2010 - 14 years ago

  3 - NOTICE OF DESIGN SEARCH CODE MAILED Type: MDSM

• 4/29/2010 - 14 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 4/27/2010 - 14 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP